Instrument Inactif

Communiqués Amryt Pharma plc London S.E.

Actions

GB00BKB1MS30_GB

GB00BKLTQ412

Produits pharmaceutiques

Communiqués

05/02/24	Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy	AQ
10/11/23	Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma	AQ
12/04/23	2022 for Chiesi, The Group's international growth continues	AQ
12/04/23	Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	GL
12/04/23	Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	GL
11/04/23	2022 for Chiesi: The Group’s international growth continues	AQ
04/04/23	Amryt Pharma Plc - High Court of Justice of England and Wales Sanctions Scheme of Arrangement	AQ
03/04/23	High Court of Justice of England and Wales Sanctions Scheme of Arrangement	GL
03/04/23	High Court of Justice of England and Wales Sanctions Scheme of Arrangement	AQ
22/03/23	Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici	GL
24/02/23	AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	BU
16/02/23	AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	GL
16/02/23	AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	AQ
11/01/23	AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	BU
08/01/23	Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	GL
08/01/23	Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	AQ
05/01/23	Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	GL
19/12/22	COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors	GL
05/12/22	European Commission approves Mycapssa® for the treatment of Acromegaly	GL
30/11/22	Amryt Announces New Patent for Mycapssa®	GL
30/11/22	Amryt Announces New Patent for Mycapssa®	GL
03/11/22	Amryt Reports Q3 2022 Financial and Operational Results	GL
03/11/22	Amryt Reports Q3 2022 Financial and Operational Results	GL
31/10/22	Amryt Supports Acromegaly Awareness Day 2022	GL
31/10/22	Amryt Supports Acromegaly Awareness Day 2022	AQ